Spots Global Cancer Trial Database for Sunitinib Malate in Treating Patients With Small Cell Lung Cancer

Study Description

Brief Summary: RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients with small cell lung cancer.

Detailed Description: OBJECTIVES: Primary * To assess the therapeutic activity of sunitinib malate in patients with either chemonaïve extensive stage or sensitive relapsed small cell lung cancer. Secondary * To characterize the safety of sunitinib malate in these patients. Tertiary * To determine the potential of FDG-PET-scan to serve as a surrogate marker of response for the antiangiogenic activity of the compound. OUTLINE: This is a multicenter study. Patients are stratified according to disease stage (chemonaïve extensive stage vs sensitive relapse at least 3 months after stopping chemotherapy). Patients receive oral sunitinib malate once daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo fludeoxyglucose F 18 positron emission tomography of the chest at week 4. Blood samples and bronchial washings and brushings may be collected at baseline and at 4 and 8 weeks after start of therapy for further analysis. After completion of study treatment, patients are followed up every 3 months.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial